Max-Planck-Institut für Kohlenforschung, 45470 Mülheim/Ruhr, Germany.
Chemistry. 2013 Jun 3;19(23):7370-83. doi: 10.1002/chem.201300393. Epub 2013 Apr 17.
Lactimidomycin (1) was described in the literature as an exquisitely potent cell migration inhibitor. Encouraged by this claim, we developed a concise and scalable synthesis of this bipartite glutarimide-macrolide antibiotic, which relies on the power of ring-closing alkyne metathesis (RCAM) for the formation of the unusually strained 12-membered head group. Subsequent deliberate digression from the successful path to 1 also brought the sister compound isomigrastatin (2) as well as a series of non-natural analogues of these macrolides into reach. A careful biological re-evaluation of this compound collection showed 1 and progeny to be potently cytotoxic against a panel of cancer cell lines, even after one day of compound exposure; therefore any potentially specific effects on tumor cell migration were indistinguishable from the acute effect of cell death. No significant cell migration inhibition was observed at sub-toxic doses. Although these findings cannot be reconciled with some reports in the literature, they are in accord with the notion that lactimidomycin is primarily a ribosome-binder able to effectively halt protein biosynthesis at the translation stage.
乳酰蜜霉素(1)在文献中被描述为一种极其有效的细胞迁移抑制剂。受此说法的鼓舞,我们开发了一种简洁且可规模化的二部分谷氨酸-大环内酯抗生素合成方法,该方法依赖于闭环炔烃复分解(RCAM)来形成异常紧张的 12 元头基。随后,我们故意偏离成功的路线,也得到了姊妹化合物异乳酰蜜他汀(2)以及这些大环内酯的一系列非天然类似物。对该化合物系列的仔细重新评估表明,1 及其衍生物对一组癌细胞系具有很强的细胞毒性,即使在化合物暴露一天后也是如此;因此,任何对肿瘤细胞迁移的潜在特异性影响都与细胞死亡的急性影响无法区分。在亚毒性剂量下没有观察到明显的细胞迁移抑制。尽管这些发现与文献中的一些报道不一致,但它们与乳酰蜜霉素主要是一种核糖体结合物的观点一致,能够在翻译阶段有效地阻止蛋白质的生物合成。